In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 25, No. 18_suppl ( 2007-06-20), p. 13509-13509
Abstract:
13509 Background: We evaluated the feasibility, safety, and immunogenicity of mature, apoptosis tumor cells-pulsed dendritic cell (DC) vaccines administered by intradermal injection. Methods: We performed a randomized study in 16 patients with malignant tumors, including 4 cases for gastric cancer, 3 cases for prostate cancer, 2 cases for breast cancers, one case for lung cancer, esophageal carcinoma, liver cancer , colorectal cancer, kidney cancer, ovarian cancer, endometrial cancer respectively.The vaccine used mature DCs (CD11c++, HLA-DR++, CD83+, and CD86+++) generated from peripheral blood monocytes in the presence of GM-CSF and IL-4. After 5 days, DCs were matured with a defined cocktail of cytokines (IL-1+ TNF-a+PGE2) and simultaneously pulsed with apoptosis autologous tumor cells or heterologous tumor cell lines, for 2 days.Patients were administrated four DC vaccinations (5×10 6 per time) at 7 th day, 14 th day, 21 st day and 42 nd day by intradermal injection(ID). Toxicity effect, life quality, immune function and clinical efficacy were monitored during the whole therapy. Results: Fourteen (82.4%) of 17 patients completed all four vaccinations. Vaccinations were well tolerated; a few patients exhibited less than grade 1 toxicities including rash, transient fever, transient debilitation and injection site reaction. The life quality of most patients had improved to certain degree, including sleep, appetite, mental status, and a good recovery from surgery and chemotherapy. Moreover, the serum level of IL-2 of 10/14 patients increased more than several times to twenty times, and 6/10 patients had a long increase for more than forty days. Serum level of IL-12 were increase in 11/14(9/11 patients increased for more than forty days) patients, Serum level of IFN-? were increase in 11/14(5/11 patients increased for more than forty days ) patients. Conclusions: Administration of this apoptosis tumor cell-pulsed mature DC vaccine by ID routes is feasible and safe. This administration seems to result in superior immunological sensitization as measured by in vitro serum level of immune cell factor such as IL-2, IL-12 and IFN-?. No significant financial relationships to disclose.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2007.25.18_suppl.13509
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2007
detail.hit.zdb_id:
2005181-5
Permalink